Panacea Acquisition II (Panacea Acquisition II) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 04, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Panacea Acquisition II 5-Year Yield-on-Cost %?

Panacea Acquisition II's yield on cost for the quarter that ended in Dec. 2022 was 0.00.

The historical rank and industry rank for Panacea Acquisition II's 5-Year Yield-on-Cost % or its related term are showing as below:

PANA's 5-Year Yield-on-Cost % is not ranked ^*
in the Diversified Financial Services industry.
Industry Median: 3.915
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Panacea Acquisition II's 5-Year Yield-on-Cost %

For the Shell Companies subindustry, Panacea Acquisition II's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panacea Acquisition II's 5-Year Yield-on-Cost % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Panacea Acquisition II's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Panacea Acquisition II's 5-Year Yield-on-Cost % falls into.

Panacea Acquisition II 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Panacea Acquisition II is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Panacea Acquisition II (NAS:PANA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Panacea Acquisition II 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Panacea Acquisition II's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Panacea Acquisition II (Panacea Acquisition II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

N/A

Address

357 Tehama Street, Floor 3, San Francisco, CA, USA, 94103

Website

Panacea Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Executives

Ecor1 Capital Fund Qualified, L.p.	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p.	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Venture Opportunity Fund, Lp	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc	director, 10 percent owner	1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Panacea Holdings Ii, Llc	director, 10 percent owner	357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Douglas E Williams	director	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Douglas E. Giordano	director	C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017
Nina S Kjellson	director	C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Praveen P. Tipirneni	director	C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Sarah Marriott	director, officer: Secretary	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Perlen	officer: Chief Financial Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Caroline Stout	officer: Chief Investment Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Platshon	officer: Chief Operating Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103